122 related articles for article (PubMed ID: 31324565)
1. Total synthesis of dryocrassin ABBA and its analogues with potential inhibitory activity against drug-resistant neuraminidases.
Hou B; Liu Z; Yang XB; Zhu WF; Li JY; Yang L; Reng FC; Lv YF; Hu JM; Liao GY; Zhou J
Bioorg Med Chem; 2019 Sep; 27(17):3846-3852. PubMed ID: 31324565
[TBL] [Abstract][Full Text] [Related]
2. Anti-Influenza Virus (H5N1) Activity Screening on the Phloroglucinols from Rhizomes of Dryopteris crassirhizoma.
Wang J; Yan YT; Fu SZ; Peng B; Bao LL; Zhang YL; Hu JH; Zeng ZP; Geng DH; Gao ZP
Molecules; 2017 Mar; 22(3):. PubMed ID: 28282885
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of NH
Wang K; Yang F; Wang L; Liu K; Sun L; Lin B; Hu Y; Wang B; Cheng M; Tian Y
Eur J Med Chem; 2017 Dec; 141():648-656. PubMed ID: 29107426
[TBL] [Abstract][Full Text] [Related]
4. Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses.
Wu Y; Bi Y; Vavricka CJ; Sun X; Zhang Y; Gao F; Zhao M; Xiao H; Qin C; He J; Liu W; Yan J; Qi J; Gao GF
Cell Res; 2013 Dec; 23(12):1347-55. PubMed ID: 24165891
[TBL] [Abstract][Full Text] [Related]
5. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Farrukee R; Butler J; Reading PC; Hurt AC
Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385
[TBL] [Abstract][Full Text] [Related]
6. Anticoronaviral Activity of the Natural Phloroglucinols, Dryocrassin ABBA and Filixic Acid ABA from the Rhizome of
Jin YH; Jeon S; Lee J; Kim S; Jang MS; Park CM; Song JH; Kim HR; Kwon S
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214108
[TBL] [Abstract][Full Text] [Related]
7. Dryocrassin ABBA Induces Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells Through a Caspase-Dependent Mitochondrial Pathway.
Jin Z; Wang WF; Huang JP; Wang HM; Ju HX; Chang Y
Asian Pac J Cancer Prev; 2016; 17(4):1823-8. PubMed ID: 27221859
[TBL] [Abstract][Full Text] [Related]
8. Application of a sensitive and accurate LC-MS/MS method for determination of dryocrassin ABBA in rat plasma for a bioavailability study.
Ding YM; Liu Z; Li FQ
Biomed Chromatogr; 2014 Sep; 28(9):1205-11. PubMed ID: 24497015
[TBL] [Abstract][Full Text] [Related]
9. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
Itoh Y; Shichinohe S; Nakayama M; Igarashi M; Ishii A; Ishigaki H; Ishida H; Kitagawa N; Sasamura T; Shiohara M; Doi M; Tsuchiya H; Nakamura S; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
Antimicrob Agents Chemother; 2015 Aug; 59(8):4962-73. PubMed ID: 26055368
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.
Wang Z; Cheng LP; Zhang XH; Pang W; Li L; Zhao JL
Bioorg Med Chem Lett; 2017 Dec; 27(24):5429-5435. PubMed ID: 29141777
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
Xiao M; Xu L; Lin D; Lian W; Cui M; Zhang M; Yan X; Li S; Zhao J; Ye J; Liu A; Hu A
Eur J Med Chem; 2021 Mar; 213():113161. PubMed ID: 33540229
[TBL] [Abstract][Full Text] [Related]
12. Dryocrassin suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival.
Fu RH; Wang YC; Liu SP; Shih TR; Lin HL; Chen YM; Tsai RT; Tsai CH; Shyu WC; Lin SZ
Cell Transplant; 2014; 23(4-5):641-56. PubMed ID: 24816456
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities.
Lin CH; Chang TC; Das A; Fang MY; Hung HC; Hsu KC; Yang JM; von Itzstein M; Mong KK; Hsu TA; Lin CC
Org Biomol Chem; 2013 Jun; 11(24):3943-8. PubMed ID: 23695381
[TBL] [Abstract][Full Text] [Related]
14. Dryocrassin ABBA, a novel active substance for use against amantadine-resistant H5N1 avian influenza virus.
Ou C; Zhang Q; Wu G; Shi N; He C
Front Microbiol; 2015; 6():592. PubMed ID: 26136733
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Biological Evaluation of
Hu Y; Chen B; Lei Z; Zhao H; Zhu H; Quan P; Tian Y
Molecules; 2019 Jun; 24(11):. PubMed ID: 31185617
[TBL] [Abstract][Full Text] [Related]
16. [Drug susceptibility of wild-type and mutant H7N9 neuraminidase to zanamivir and oseltamivir].
Wei YN; Zhang C; Chen Q; Guo Y
Bing Du Xue Bao; 2014 Jul; 30(4):396-401. PubMed ID: 25272593
[TBL] [Abstract][Full Text] [Related]
17. Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment.
Liu Q; Ma J; Strayer DR; Mitchell WM; Carter WA; Ma W; Richt JA
Expert Rev Anti Infect Ther; 2014 Feb; 12(2):165-9. PubMed ID: 24350808
[TBL] [Abstract][Full Text] [Related]
18. Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors.
Li Z; Meng Y; Xu S; Shen W; Meng Z; Wang Z; Ding G; Huang W; Xiao W; Xu J
Bioorg Med Chem; 2017 May; 25(10):2772-2781. PubMed ID: 28385598
[TBL] [Abstract][Full Text] [Related]
19. Novel N-Substituted oseltamivir derivatives as potent influenza neuraminidase inhibitors: Design, synthesis, biological evaluation, ADME prediction and molecular docking studies.
Ye J; Yang X; Xu M; Chan PK; Ma C
Eur J Med Chem; 2019 Nov; 182():111635. PubMed ID: 31493744
[TBL] [Abstract][Full Text] [Related]
20. A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
Sriwilaijaroen N; Magesh S; Imamura A; Ando H; Ishida H; Sakai M; Ishitsubo E; Hori T; Moriya S; Ishikawa T; Kuwata K; Odagiri T; Tashiro M; Hiramatsu H; Tsukamoto K; Miyagi T; Tokiwa H; Kiso M; Suzuki Y
J Med Chem; 2016 May; 59(10):4563-77. PubMed ID: 27095056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
